Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
Authors:
Open Access
- 20 July 2023
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 26 (3) , 1-18
Abstract
Immune checkpoint inhibitors (ICIs) are among the most notable advances in cancer immunotherapy; however, reliable biomarkers for the efficacy of ICIs are yet to be reported. Programmed death (PD)‑ligand 1 (L1)‑expressing CD14+ monocytes are associated with shorter overall survival (OS) time in patients with cancer treated with anti‑PD‑1 antibodies. The present study focused on the classification of monocytes into three subsets: Classical, intermediate and non‑classical. A total of 44 patients with different types of cancer treated with anti‑PD‑1 monotherapy (pembrolizumab or nivolumab) were enrolled in the present study. The percentage of each monocyte subset was investigated, and the percentage of cells expressing PD‑L1 or PD‑1 within each of the three subsets was further analyzed. Higher pretreatment classical monocyte percentages were correlated with shorter OS (r=‑0.32; P=0.032), whereas higher non‑classical monocyte percentages were correlated with a favorable OS (r=0.39; P=0.0083). PD‑L1‑expressing classical monocytes accounted for a higher percentage of the total monocytes than non‑classical monocytes with PD‑L1 expression. In patients with non‑small cell lung cancer (NSCLC), a higher percentage of PD‑L1‑expressing classical monocytes was correlated with shorter OS (r=‑0.60; P=0.012), which is similar to the observation for the whole patient cohort. Comparatively, higher percentages of non‑classical monocytes expressing PD‑L1 were significantly associated with better OS, especially in patients with NSCLC (r=0.60; P=0.010). Moreover, a higher percentage of non‑classical monocytes contributed to prolonged progression‑free survival in patients with NSCLC (r=0.50; P=0.042), with similar results for PD‑L1‑expressing non‑classical monocytes. The results suggested that the percentage of monocyte subsets in patients with cancer before anti‑PD‑1 monotherapy may predict the treatment efficacy and prognosis. Furthermore, more classical monocytes and fewer non‑classical monocytes, especially those expressing PD‑L1, are involved in shortening OS time, which may indicate the poor efficiency of anti‑PD‑1 treatment approaches.Keywords
This publication has 57 references indexed in Scilit:
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 AxisClinical Cancer Research, 2013
- Monocytes and Macrophages in Cancer: Development and FunctionsCancer Microenvironment, 2012
- The three human monocyte subsets: implications for health and diseaseImmunologic Research, 2012
- Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag levelGynecologic Oncology, 2012
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Nomenclature of monocytes and dendritic cells in bloodBlood, 2010
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammationBlood, 2008
- Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinomaSurgery, 2006